The chart below shows how ITGR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ITGR sees a -1.98% change in stock price 10 days leading up to the earnings, and a +2.61% change 10 days following the report. On the earnings day itself, the stock moves by +0.70%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Sales Growth Performance: Sales grew 9% year-over-year in Q3 2024, contributing to a year-to-date sales growth of 10%.
Operating Income Surge: Adjusted operating income increased by 17% in Q3 2024, with year-to-date operating income up 23%, significantly outpacing sales growth.
Adjusted EBITDA Increase: Adjusted EBITDA for Q3 2024 was $96 million, reflecting an 18% increase compared to the prior year, while year-to-date adjusted EBITDA rose by 22%.
Earnings Per Share Outlook: The company raised its adjusted earnings per share outlook to a growth of 16% year-over-year, increasing the midpoint by $0.07 per share over previous guidance.
Cash Flow Increase: Integer generated $72 million in cash flow from operations in Q3 2024, a $9 million increase from the previous year, and $142 million year-to-date, marking a 14% increase.
Negative
Organic Sales Decline: 1. Declining Organic Growth: Organic sales growth for Q3 2024 was only 4%, a significant drop from the year-to-date growth of 6%, primarily due to a decrease in demand for Cardiac Rhythm Management products and the impact of Hurricane Helene.
Rising Interest Expenses: 2. Increased Interest Expense: Year-to-date interest expense rose by approximately $7 million compared to the previous year, attributed to a higher average debt balance resulting from acquisitions, which negatively impacted net income growth.
Hurricane Operational Disruptions: 3. Hurricane Impact on Operations: The closure of facilities due to Hurricane Helene at the end of Q3 resulted in a 1% shortfall in organic growth, with lingering cost pressures expected in Q4 as operations ramp back up.
Operating Income Margin Decline: 4. Lower Adjusted Operating Income Margin: Despite a year-to-date adjusted operating income margin improvement to 16.5%, the Q3 margin was only 17.5%, indicating a slower pace of margin expansion compared to previous quarters.
Decline in R&D Revenue: 5. Reduced R&D Revenue: R&D revenues were lower in Q3 due to higher customer reimbursements for development work, leading to a nominal decrease in reported R&D expenses, which may signal a potential slowdown in future R&D investment.
Integer Holdings Corporation (ITGR) Q3 2024 Earnings Call Transcript
ITGR.N
-3.96%